Form 4: Blueprint Medicines CEO Kate Haviland Sells Shares to Cover Tax Obligations

Kate Haviland, CEO of Blueprint Medicines, sold 12,464 shares of common stock on March 7, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On March 7, 2024, Kate Haviland, the CEO of Blueprint Medicines, sold 12,464 shares of the company's common stock.
• The sale was executed at a price of $90.69 per share.
• This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the sale, Haviland directly owns 153,177 shares of Blueprint Medicines.
• A Limited Power of Attorney was executed on January 31, 2023, granting certain individuals the authority to act on Haviland's behalf in matters related to Section 13 and Section 16 of the Securities Exchange Act of 1934.

Sentiment

Score: 6

Explanation: The document primarily reports a routine transaction (stock sale for tax obligations). It doesn't contain overtly positive or negative information about the company's performance or future prospects. Therefore, a neutral sentiment score is appropriate.

Industry Context

Executive stock sales are a common occurrence, often related to compensation and tax planning. The sale itself doesn't necessarily indicate a negative outlook for the company, as it's often a planned part of an executive's financial strategy.

Stakeholder Impact

• The stock sale may have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect on shareholders.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates